Monograph Details
|
|
Neoplasms
> Alkylating agents
|
|
LEUKERAN |
| Manufacturer |
|
GlaxoSmithKline Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Alkylating agent. |
| Generic Name |
|
Chlorambucil 2mg; tabs. |
| Indications |
|
Palliative treatment of chronic lymphatic (lymphocytic) leukemia and malignant lymphomas (including lymphosarcoma, giant follicular lymphoma, and Hodgkin's disease). |
| Children |
|
Not recommended. |
| Adults |
|
See literature. 0.1–0.2mg/kg per day for 3–6 weeks. Reduce dose if leukocyte or platelet counts fall below normal values and discontinue if more severe depression occurs. Do not give full dose within 4 weeks of radio- or chemotherapy. |
| Precautions |
|
Compromised bone marrow function. History of seizure disorder or head trauma. Monitor blood weekly (during first 3–6 weeks, do WBC count 3–4 days after each weekly CBC). Discontinue if skin reactions occur. Elderly. Pregnancy (Cat.D), nursing mothers: not recommended. |
| Interactions |
|
Avoid live vaccines. Myelosuppressives, radiotherapy potentiate antineoplastic effect. Caution with drugs that lower seizure threshold. |
| Adverse Reactions |
|
Bone marrow suppression, seizures, fever, rash, hypersensitivity, urticaria, azoospermia, amenorrhea, sterility, hepato- and pulmonary toxicity, secondary malignancies, GI upset. |
| How Supplied |
|
Tabs—50 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
